Skip to main content

Table 2 Clinical features of LC patients by HR type HPV DNA status and p16 immunohistochemistry

From: High-risk type human papillomavirus infection and p16 expression in laryngeal cancer

  All cases (n = 88) HR-HPV (+) (n = 16)   HR-HPV−/p16 - (n = 72)
HR-HPV+/p16+ (n = 5) HR-HPV+/p16- (n = 11)
Sex
 Male 82 16 5 11 66
 Female 6 0 0 0 6
Age (years)
  < 66 39 9 4 5 30
  ≥ 66 49 7 1 6 42
T
 T1, T2 63 11 3 8 52
 T3, T4 25 5 2 3 20
N
 N0, N1 77 14 4 10 63
 N2, N3 11 2 1 1 9
Tumor subsite
 Supraglottis 22 3 1 2 19
 Glottis 59 12 4 8 47
 Subglottis 7 1 0 1 6
Stage
 I, II 59 11 1 8 48
 III, IV 29 5 2 3 24
Smoking habit
(pack years)
  < 40 39 10 3 6 29
  ≥ 40 49 6 0 5 43
Alcohol consumption (g/day)
  < 40 50 9 3 5 41
  ≥ 40 38 7 0 6 31
Primary treatment
 Surgery±RT/CCRT
CCRT to Surgery
40 6 2 4 34
 RT or CCRT 48 10 1 7 38
5-year cumulative survival (%) 80.7 87.5 100 81.8 79.5